RCKT vs. PAHC, SDGR, HROW, SNDX, EVO, ZYME, AVDL, TSHA, ORIC, and SION
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Phibro Animal Health (PAHC), Schrodinger (SDGR), Harrow (HROW), Syndax Pharmaceuticals (SNDX), Evotec (EVO), Zymeworks (ZYME), Avadel Pharmaceuticals (AVDL), Taysha Gene Therapies (TSHA), Oric Pharmaceuticals (ORIC), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry.
Rocket Pharmaceuticals vs. Its Competitors
Phibro Animal Health (NASDAQ:PAHC) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.
Phibro Animal Health has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Phibro Animal Health has a net margin of 3.73% compared to Rocket Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 32.14% beat Rocket Pharmaceuticals' return on equity.
99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 24.8% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Phibro Animal Health currently has a consensus target price of $28.40, indicating a potential downside of 29.79%. Rocket Pharmaceuticals has a consensus target price of $16.67, indicating a potential upside of 313.05%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Phibro Animal Health.
Phibro Animal Health has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
In the previous week, Rocket Pharmaceuticals had 4 more articles in the media than Phibro Animal Health. MarketBeat recorded 9 mentions for Rocket Pharmaceuticals and 5 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.32 beat Rocket Pharmaceuticals' score of 0.26 indicating that Phibro Animal Health is being referred to more favorably in the media.
Summary
Phibro Animal Health beats Rocket Pharmaceuticals on 12 of the 16 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RCKT) was last updated on 10/20/2025 by MarketBeat.com Staff
